Resistin Levels in Human Immunodeficiency Virus-Infected Patients with Lipoatrophy Decrease in Response to Rosiglitazone

• Published in: The journal of clinical endocrinology and metabolism Vol. 90; no. 6; pp. 3423 - 3426
• Main Authors: Kamin, Daniel, Hadigan, Colleen, Lehrke, Michael, Mazza, Sasha, Lazar, Mitchell A., Grinspoon, Steven
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Endocrine Society 01-06-2005
• Subjects: Adult; Biological and medical sciences; CD4 Lymphocyte Count; Diabetes Mellitus, Lipoatrophic - drug therapy; Diabetes Mellitus, Lipoatrophic - etiology; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; HIV Infections - complications; HIV Infections - drug therapy; Hormones, Ectopic - blood; Human immunodeficiency virus; Humans; Hypoglycemic Agents - therapeutic use; Male; Medical sciences; Middle Aged; PPAR gamma - antagonists & inhibitors; Resistin; Thiazolidinediones - therapeutic use; Vertebrates: endocrinology; Human; Adipocytokine; Immunopathology; Skin disease; Patient; AIDS; Thiazolidinedione derivatives; Immune deficiency; Infection; Lipoatrophy; Viral disease; Rosiglitazone; Adipose tissue disorders; Endocrinology; Resistin
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2005-0287

Resistin is a recently recognized adipocytokine thought to contribute to insulin resistance. We determined resistin levels and metabolic parameters in 24 HIV-infected men and women with lipoatrophy and hyperinsulinemia and studied the effect of 12 wk of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone (4–8 mg/d) on resistin in these subjects. Participants completed metabolic testing before and after rosiglitazone including fasting determination of resistin, adiponectin, and leptin levels, serum inflammatory markers, and hyperinsulinemic euglycemic clamp testing. Resistin concentration decreased significantly after rosiglitazone (12.17 ± 1.15 ng/ml to 10.23 ± 1.05 ng/ml; P = 0.02), in conjunction with significant increases in adiponectin- (P < 0.001) and insulin- stimulated glucose disposal (P = 0.004). Leptin levels, as well as TNF-α, did not change with rosiglitazone. In summary, among HIV-infected subjects with insulin resistance and lipoatrophy, resistin levels decreased significantly after rosiglitazone. Further investigation into the physiological role of this peroxisome proliferator-activated receptor-γ-responsive adipocytokine in the metabolic abnormalities associated with HIV is warranted.